Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bridgebio Pharma (BBIO)
:BBIO
Holding BBIO?
Track your performance easily
BBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$21.62 - $41.04
Previous CloseN/A
Volume379.31K
Average Volume (3M)2.32M
Market Cap
$6.45B
Enterprise Value$6.14B
Total Cash (Recent Filing)$92.00M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Feb 20, 2025EPS Estimate
-1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.41
Shares Outstanding188,989,800
10 Day Avg. Volume3,516,262
30 Day Avg. Volume2,316,544
Standard Deviation0.24
R-Squared0.06
Alpha0.00910
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)29.60
Price to Cash Flow (P/CF)-8.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue28.17
Enterprise Value/Gross Profit894.71
Enterprise Value/Ebitda-16.82
Forecast
1Y Price Target
$50.64Price Target Upside49.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
BridgeBio Pharma News
PremiumCompany Announcements
BridgeBio Pharma Reports Strong Drug Uptake and Trial Progress
Bulls Say, Bears Say
Bulls Say
Clinical TrialsBBP-418 and Encaleret PhIII data could drive upside, enhancing company prospects.
Launch PerformanceManagement announced 430 Attruby prescriptions at ~1mo post-launch, indicating strong initial uptake.
Regulatory ApprovalsPotential EU and JP approvals could provide BBIO with $105M in milestones, accelerating growth.
Bears Say
CompetitionThe company's two key assets, acoramidis and infigratinib face competitive markets with entrenched players if both drugs are approved and commercialized.
Financial ConcernsMessy financials add further risk, with a cash burn of approximately $200M per quarter and a substantial debt balance that includes $1.3B converts due to be refinanced.
Intellectual Property RisksThe biggest challenge for Attruby is Pfizer's intellectual property case for tafamidis, which may impact its competitive edge.
---
Ownership Overview
20.77% Insiders
15.70% Mutual Funds
0.07% Other Institutional Investors
49.78% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BBIO FAQ
What was Bridgebio Pharma’s price range in the past 12 months?
Bridgebio Pharma lowest stock price was $21.62 and its highest was $41.04 in the past 12 months.
What is Bridgebio Pharma’s market cap?
Bridgebio Pharma’s market cap is $6.45B.
When is Bridgebio Pharma’s upcoming earnings report date?
Bridgebio Pharma’s upcoming earnings report date is Feb 20, 2025 which is in 30 days.
How were Bridgebio Pharma’s earnings last quarter?
Bridgebio Pharma released its earnings results on Nov 12, 2024. The company reported -$0.86 earnings per share for the quarter, beating the consensus estimate of -$1.003 by $0.143.
Is Bridgebio Pharma overvalued?
According to Wall Street analysts Bridgebio Pharma’s price is currently Undervalued.
Does Bridgebio Pharma pay dividends?
Bridgebio Pharma does not currently pay dividends.
What is Bridgebio Pharma’s EPS estimate?
Bridgebio Pharma’s EPS estimate is -1.13.
How many shares outstanding does Bridgebio Pharma have?
Bridgebio Pharma has 188,989,800 shares outstanding.
What happened to Bridgebio Pharma’s price movement after its last earnings report?
Bridgebio Pharma reported an EPS of -$0.86 in its last earnings report, beating expectations of -$1.003. Following the earnings report the stock price went down -5.743%.
Which hedge fund is a major shareholder of Bridgebio Pharma?
Among the largest hedge funds holding Bridgebio Pharma’s share is Viking Global Investors LP. It holds Bridgebio Pharma’s shares valued at 640M.
---
BridgeBio Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.64 (49.87% Upside)
$50.64 (49.87% Upside)
Blogger Sentiment
Bullish
BBIO Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 5.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 8.5%
Last 30 Days ▲ 8.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.45%
12-Months-Change
Fundamentals
Return on Equity
35.68%
Trailing 12-Months
Asset Growth
1.52%
Trailing 12-Months
Company Description
Bridgebio Pharma
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
---
BBIO Stock 12 Month Forecast
Average Price Target
$50.64
▲(49.87% Upside)
Technical Analysis
Allogene Therapeutics
―
Blueprint Medicines
―
Kura Oncology
―
RAPT Therapeutics
―
Relay Therapeutics
―
Sarepta Therapeutics
―
Best Analysts Covering BBIO
1 Year
1 Year Success Rate
12/14 ratings generated profit
1 Year Average Return
+32.29%
reiterated a buy rating 2 months ago
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +32.29% per trade.
---